FAIRFIELD, N.J., April 27 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company launched Centany(R) (mupirocin ointment, 2%) and Uramaxin(TM) (20% Urea) Foam to its core Dermatology and Podiatry physician audiences. Centany(R) received a New Drug Approval in December 2002 and is patented through 2018. Centany(R) represents a significant step in Medimetriks' plan to commercialize patent-protected therapies that offer important patient benefits. Uramaxin(TM) Foam represents a valuable addition to the Company's Uramaxin(TM) Family of urea-based brands. Both of these brands come to Medimetriks as the result of a licensing agreement with Perrigo Company for U.S. marketing rights.
Centany(R), previously marketed by Johnson & Johnson's Ortho Dermatologics professional division, is indicated for the topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. In addition to a 94% clinical efficacy rate(1) and a 98% eradication of staph and strep*, Centany(R) provides an enhanced safety profile over other mupirocin-based therapies. Centany(R) is the only mupirocin ointment indicated for impetigo free of polyethylene glycol(2), an ingredient found in other mupirocin ointments that carry warnings for patients with impaired kidney function. Centany(R)'s unique vehicle also offers the cosmetically elegant texture of a cream with the occlusive properties of an ointment, providing patients with a therapeutic alternative that may enhance patient compliance. Based on the unique properties of its vehicle, Centany(R) is BX-rated by the FDA and designated as non-substitutable.
Uramaxin(TM) Foam is 20% urea in a vehicle containing ammonium lactate. These components make up the vast majority of prescriptions written by Dermatologists and Podiatrists for dry skin conditions. Uramaxin(TM) Foam is an effective, low-potency keratolytic that complements Uramaxin(TM) (45% Urea) Nail Gel and Uramaxin(TM) (45% Urea) Cream, high-potency keratolytics previously launched by the Company. The foam delivery system is a format gaining wide acceptance by both physicians and patients, and Uramaxin(TM) Foam is provided in a large size to add value to patients. Uramaxin(TM) Foam will compete in a skin softening market that approaches one million prescriptions annually.
Medimetriks CEO and Chairman, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio of therapies that provide value to both patients and physicians. Since the introduction of Medimetriks on May 1st of 2008, the Company has now launched six prescription therapies. These brands will be promoted by an expanding field force that we expect to reach more than 30 professional representatives within the next nine months."
*One week after therapy.
(1)Centany(R) Prescribing Information, Fairfield, NJ: Medimetriks Pharmaceuticals, October 2008.
(2)Data on file, Medimetriks Pharmaceuticals.
Centany(R) is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of Centany(R): application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.
Uramaxin(TM) Foam is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappears after discontinuing the medication.
Please see full prescribing information at www.medimetriks.com
About Medimetriks Pharmaceuticals, Inc.
Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.
The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.
CONTACT: David Addis, Senior Vice President, Brand Communication,
Medimetriks Pharmaceuticals, Inc., +1-973-882-7512, ext. 569
Web site: http://www.medimetriks.com/